Brief Description
"This book is about benefit and risk. More precisely, this book is about the definition, assessment, balance and communication of favorable and unfavorable consequences of treatments in pharmaceutical research and development. This book is not a definitive treatise on benefit and risk in pharmaceutical research and development. It is not a prescriptive guide for characterizing the benefits and risks of a molecule under development. Nor is it a collection of best practices and recommendations for a successful benefit and risk assessment. It is a gateway. It is a gateway that opens into a long corridor that chronicles the concepts, assessment methods, interpretations and implications of benefits and risks as a molecule journeys from concept to customer. Along the corridor are four doors that open into four galleries. Depending upon our experiences and state of mind, these doors may appear dark and foreboding, etched with esoteric runes and rubbed with mystic herbs... or curious and unusual entryways we've walked by for years yet never thought to enter... or enticing and accessible points of access to newly revealed vistas abundant with challenge and promise. Each door in the corridor will bear one of four brass plates: Early Clinical Development, Full Clinical Development, Regulatory Review and Policy, Post Launch Assessment. In the Early Clinical Development gallery, we will encounter interpretations of benefit and risk in the context of a molecule moving from discovery through its preclinical evaluation and its initial testing in man. The Full Clinical Development door opens into a gallery that considers benefit and risk during a molecule's journey from its entry into man until it is submitted to regulators for approval"--
Learn More about the Book
Many practitioners in the pharmaceutical industry are still largely unfamiliar with benefit-risk assessment, despite its growing prominence in drug development and commercialization. Helping to alleviate this knowledge gap, Benefit-Risk Assessment in Pharmaceutical Research and Development provides a succinct overview of the key considerations relevant to benefit-risk assessment across the pharmaceutical R&D spectrum, from early clinical development to late-stage development to regulatory review to post-launch assessment.
The book first presents interpretations of benefit and risk in the context of a molecule moving from preclinical evaluation into its early testing in humans. It next considers benefit and risk characterization and assessment during a molecule s journey from its clinical evaluation in humans through its submission to regulators for marketing approval. Throughout these sections, the book offers insight into the role of benefit-risk assessment in heightening understanding among key stakeholders by shaping questions and guiding discussions among scientists, physicians, developers, and regulatory agencies. The book also focuses on a molecule s entry into the marketplace as a drug available for consumption by people. It explores the role of benefit-risk assessment as the relevance of carefully collected clinical efficacy and safety metrics fades in the wake of real-world use and evidence of effectiveness and safety.
Bringing together the expertise of 15 contributors from academia and the industry, this book offers an easy-to-read guide to the various facets of benefit-risk assessment in the major stages of pharmaceutical R&D. Suitable for those in both technical and managerial roles, it enables readers to communicate more effectively across their development chain as well as rationally and thoughtfully embed benefit-risk assessment into their R&D processes.
"
Review Quotes
1.
"I think this text makes a strong case for the increasing importance of formal (and potentially quantitative) B-R assessment readers new to B-R will get a well-rounded perspective of the key considerations and challenges to performing these assessments from thorough discussion of the overarching principles, different perspectives, and work to date. The authors identify several gaps, such as the emerging need to include patient perspective into the equation, and acknowledge that there are no universally accepted statistical methods at this time. Whether you are completely new to B-R or whether you are trying to implement quantitative methods at the company or project level, this book will be useful for statisticians charged with supporting these assessments now and in the future."
Pharmaceutical Statistics, 2014
"
